Recent Advances in Drug Therapy for Parkinson's Disease.

Intern Med · 2023 · PMC9876715 · PMID 35110492

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

may be significantno p-value reported

Improvement of motor symptoms by MAO-B inhibitor monotherapy as first-line treatment may be poor and lead to the requirement for concomitant levodopa or a dopamine agonist in some cases, but use of a MAO-B inhibitor from the early stage may be significant for the long-term course.

also in 13,097 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.